Chemotherapeutic Agents

  • Adrienne B. Warrick
  • Karina Gritsenko
  • Melinda Aquino


Oncologic patients comprise a consistent if not significant portion of surgical patients. Many of these patients will have undergone perioperative treatment for their diseases by means of chemotherapy, radiation therapy, or a combination of the two. With regard to the chemotherapeutic agents, specific preoperative, intraoperative, and postoperative anesthetic considerations must be taken when providing care to this special subset of surgical patients.


Epidermal Growth Factor Receptor National Comprehensive Cancer Network Alkylating Agent Interstitial Cystitis Thymidine Phosphorylase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material


  1. 1.
    Anderson MR, et al. Anesthesia for patients undergoing orthopedic oncologic surgeries. J Clin Anesth. 2010;22:565–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345–52. doi: 10.1038/nri2747. PMID 20414207.PubMedCrossRefGoogle Scholar
  3. 3.
    Brunton LL, et al. Goodman & Gilman’s pharmacologic basis of therapeutics. 12th ed. New York: McGraw Hill Companies; 2011.Google Scholar
  4. 4.
    Clowse MB, Stone JH. General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases. UptoDate. 2013.Google Scholar
  5. 5.
    Hay JG, Haslam PL, Dewar A, et al. Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats. Thorax. 1987;42:374–82.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Hines RL, Marschall KE. Stoelting’s anesthesia and co-existing disease. 5th ed. Philadelphia: Churchill Livingstone; 2008.Google Scholar
  7. 7.
    Katsung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology. 11th ed. New York: McGraw Hill Medical; 2009.Google Scholar
  8. 8.
    Murillo O, et al. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res. 2003;9:5454–64.PubMedGoogle Scholar
  9. 9.
    NCCN Clinical Practice Guidelines in Oncology. Version 1.2012 – Head and Neck Cancers; Version 1.2013 – Breast Cancer; Version 2.2012 – Acute lymphoblastic Leukemia; Version 1.2013 – Acute Myeloid Leukemia; Version 3.2013 – Chronic Myelogenous Leukemia; Version 3.2013 – Colon Cancer; Version 2.2012 – Esophageal Cancer; Version 2.2012 – Gastric Cancer; Version 4.2014 – Rectal Cancer; Version 2.2013 – Small Cell Lung Cancer; Version 2.2013 – Non-Small Cell Lung Cancer; Version 1.2012 – Testicular Cancer; Version 1.2013 – Prostate Cancer; Version 1.2013 – Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer; Version 3.2012 – Uterine Neoplasms; Version 2.2012 – Cervical Cancer; Version 1.2013 – Kidney Cancer; Version 1.2013 – Central Nervous System Cancers; Version 3.2012 – Soft Tissue Sarcoma; Version 2.2013 – Bone Cancer.Google Scholar
  10. 10.
    Stoelting RK, Hillier SC. Pharmacology and physiology in anesthetic practice. 4th ed. Baltimore: Lippincott Williams & Wilkins; 2006. p. 551–68.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Adrienne B. Warrick
    • 1
  • Karina Gritsenko
    • 2
  • Melinda Aquino
    • 1
  1. 1.Department of AnesthesiologyMontefiore Medical Center, Albert Einstein College of Medicine – Yeshiva UniversityBronxUSA
  2. 2.Department of Family and Social MedicineMontefiore Medical Center, Albert Einstein College of Medicine – Yeshiva UniversityBronxUSA

Personalised recommendations